BofA warns Fed risks policy mistake with early rate cuts
JERUSALEM - Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a small-cap biotech company with a market capitalization of $1.91 million, announced Tuesday that a new peer-reviewed article in the Journal of Dermatological Treatment validates the potential of its PC111 antibody as a treatment for pemphigus and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). According to InvestingPro data, the company maintains a fair financial health score despite challenging market conditions.
The publication, authored by Dr. Roberta Lotti and colleagues from the University of Modena and Pincell Srl, builds on previous award-winning research and confirms PC111’s ability to prevent blister formation in multiple models of pemphigus by targeting soluble Fas Ligand, a key factor in skin cell damage.
The research introduces new data from a humanized mouse model in which PC111 significantly reduced disease activity. Unlike current treatments that rely on systemic immunosuppression, PC111 acts locally at the skin cell level without suppressing the immune system.
"This new publication further validates our conviction that PC111 has the potential to transform the treatment landscape for pemphigus and SJS/TEN," said Amir Reichman, CEO of Scinai, according to the press release.
The company noted that PC111 has already received orphan drug designation in the EU and plans to pursue similar status in the U.S. Scinai and Pincell are exploring accelerated approval pathways that could potentially allow market entry within approximately three to four years. The stock, currently trading at $2.05, has experienced significant volatility, with a year-to-date decline of 38.71%. InvestingPro subscribers can access 8 additional key insights about SCNI’s financial performance and market position.
The development program may receive financial support through a €15 million grant that would cover up to 80% of costs through IND readiness, with a final decision expected in the third quarter of 2025.
Scinai has an option to acquire Pincell, which would integrate the development team behind PC111 into the company.
Current treatments for pemphigus and SJS/TEN typically include steroids and other immunosuppressive medications that can have serious side effects. According to the company statement, the combined annual market opportunity for these indications exceeds one billion dollars. Based on InvestingPro’s Fair Value analysis, SCNI appears undervalued at current levels, despite operating with negative gross profit margins of -88.15%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.